Table 1.

Baseline characteristics of randomly assigned participants

	IMRT group n = 30		3D group n = 30		p-value
	n	%	n	%
Age (years)					0.219
Mean (SD)	66,1 (10,5)		62,5 (11,8)
Karnofsky-Perfomance Status					0.283
Mean (SD)	64,9 (9,32)		61,3 (9,7)
Gender					0.795
Male	17	56,7	16	53,3
Female	13	43,3	14	46,7
Weight (kg, SD)	75,8 (14,9)		76,2 (19,4)		0.929
Height (cm, SD)	171,6 (8,8)		172,2 (8,6)		0.790
Body mass index (BMI)					0.960
Mean (SD)	25,7 (4,4)		25,6 (5,7)
Primary site
Lung cancer	11	36,7	16	53,3
ABreast cancer	7	23,3	6	20
Prostata cancer	6	20	1	3,3
Other	6	20	7	23,3
Volume of metastases at baseline
Mean size (mm3)	30	1166,6	30		0.191
Localization metastases					0.261
Cervical	4	13,3	5	16,7
Thoracic	15	50	15	50
Lumbar	11	36,7	7	23,3
Sacrum	0	0	3	10
Number metastases					0.140
1 metastase	17	56,7	10	33,3
2 metastases	4	13,3	9	30
3 metastases	9	30	11	36,7
Distant metastases at baseline
Viszeral	14	46,7	10	33,3	0.292
Lung	7	23,3	6	20	0.754
Brain	4	13,3	5	16,7	0.718
Tissue	5	16,7	5	16,7	1.000
Hormontherapy	12	40	6	20	0.091
Immuntherapy	4	13,3	5	16,7	0.718
Chemotherapy	14	46,7	20	66,7	0.118
Surgery	18	60	13	43,3	0.196
Neurological deficit at baseline	4	13,3	3	10	0.688
Bisphosphonate at baseline	13	43,3	7	23,3	0.100
Orthopedic corset at baseline	9	30	10	33,3	0.781
Medication at baseline
Sleeping medication	5	16,7	2	6,7	0.228
Psychiatric medication	9	30	6	20	0.371
Opiate	20	66,7	17	56,7	0.426
NSAID	23	76,7	19	63,3	0.260

Explanation: Others: carcinoma of unknown primary (CUP), gastrointestinal stromal tumor (GIST), melanoma, mesothelioma, pancreatic cancer, renal cancer. Abbreviations: NSAID nonsteroidal inflammatory drug